knowledge -WSS

knowledge

author：hotspot 2025-08-08 08:10:11 - browse：6

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Study suggests new cause of Down syndrome: cells linked to aging

WSS

Medicare Advantage coverage denials need scrutiny, senators say

At JPM 2024, hospital systems pitch financial strength to investors

At JPM 2024, hospital systems pitch financial strength to investors

CDC recommends rationing of RSV shot due to shortages

The pink breast cancer awareness ribbon needs a redesign

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

knowledge

entertainment

Hollywood unions extend contract negotiations for actors

Meta's Zuckerberg and Chan on track to put $50 billion into science

Activists slam private health insurers over coverage restrictions

Medicare Advantage overpayments discussion gets experts fired up

Apple is now the first public company to be valued at $3 trillion

First Opinion Podcast: How to protect health care in times of war

Guidelines to prevent youth baseball injuries need more muscle

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Wildfire smoke exposes gaps in outdoor worker protections

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

Life science postdocs should get big pay hike, NIH panel says

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare Advantage overpayments discussion gets experts fired up

The FDA weighs the risks of candy

Profiling embryos to choose those with higher IQs is almost a reality

Ascension's ugly legal battle over care for poor patients in Texas

focus

leisure time

hotspot

hotspot